The PROSPER and SPARTAN studies are impacting standard of care

The PROSPER and SPARTAN studies are impacting standard of care

obr

1 year
87 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Tomasz M. Beer, MD, talks about how the the PROSPER (enzalutamide) and SPARTAN (apalutamide) studies in non-metastatic castrate-resistant prostate cancer are impacting standard of care at Annual Meeting 2018.
Up Next Autoplay